Management of adverse events associated with idelalisib treatment: expert panel opinion

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing informati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Lymphoma
Main Authors: Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2015
Fag:
Reviews
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4732460/
https://ncbi.nlm.nih.gov/pubmed/25726955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1022770
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker